Mentice Year-end Report Q4, Oct - Dec 2024
Read more
Mentice Secures $648,410 USD Combined Order for Advanced Simulation Solutions from a Top 20 Global MedTech company
Learn More
English / Svenska
Investor > Press Releases >
Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company

Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company

Tuesday, April 2, 2024

Mentice (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that a global healthcare technology leader and existing customer of Mentice has signed an agreement to acquire Mentice VIST® development services for USD 795,000.

“This order represents further support for improved patient safety from one of our largest global customers where investment in advanced training solutions are a strategic part of implementation and adoption of new medical device solutions”, states Göran Malmberg, CEO of Mentice AB.


The order will be recognized for the Medical Device Industry business area during the first quarter of 2024, and most of the revenues will be recognized in 2024.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-02 08:30 CEST.

Attachments
Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company

SHARE INFORMATION
The StockTop 10 ShareholdersCertified Advisor
PRESS RELEASES
All2022202120202019
FINANCIAL CALENDAR
Financial Calendar
financial reports
All
2022
2021
2020
2019
2023
2024
2025
CORPORATE GOVERNANCE
Corporate GovernanceArticle of AssociationGeneral MeetingsBoard of DirectorsSenior ManagementAuditorsBoard CommitteesCorporate Share HoldingsGuidelines for RemunerationNomination CommitteeSustainabilityMedia
other
About usContactCompany PresentationBack to Mentice
Data PolicyQuality PolicyDisclaimerTerms
Copyright © 2023 Mentice AB (publ) . All rights reserved.
Mentice Bokslutskommuniké, Jan - Dec 2024
Läs mer
Mentice får en total order på avancerade simuleringslösningar värd $648,410 USD från ett topp 20 globalt medtech bolag
Läs Mer
English / Svenska
Investor > Pressmeddelanden >
Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company

Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company

Tuesday, April 2, 2024

Mentice (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that a global healthcare technology leader and existing customer of Mentice has signed an agreement to acquire Mentice VIST® development services for USD 795,000.

“This order represents further support for improved patient safety from one of our largest global customers where investment in advanced training solutions are a strategic part of implementation and adoption of new medical device solutions”, states Göran Malmberg, CEO of Mentice AB.


The order will be recognized for the Medical Device Industry business area during the first quarter of 2024, and most of the revenues will be recognized in 2024.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-02 08:30 CEST.

Attachments
Mentice receives an order of USD 795,000 for development services from a world-leading MedTech company

AKTIEINFORMATION
AktieinformationTop 10 AktieägareCertifierad RådgivareIncitamentsprogram för anställda
PRESSMEDDELANDEN
Alla2022202120202019
FINASIELL KALENDER
Finansiell kalender
FINANSIELLA RAPPORTER
Alla
2022
2021
2020
2019
2023
2024
2025
BOLAGSSTYRNING
BolagsstyrningBolagsordningBolagsstämmorStyrelseKoncernledningRevisorerStyrelseutskottStyrelsens AktieägandeRiktlinjer för ersättningValberedningHållbarhetMedia
ANNAT
KontaktFöretags PresentationTillbaka till Mentice
Data PolicyQuality PolicyDisclaimerTerms
Copyright © 2022 Mentice AB (publ) . All rights reserved.